Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[1]
L.C. Iglesias , V. Arrazubi, N. Baste, A. Carral, B. Cirauqui, Y. Escobar, et al.
SEOM clinical guidelines for the treatment of head and neck cáncer (2017).
Clin Transl Oncol., (2018), 20 pp. 75-83
[2]
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17346 patients.
Radiother Oncol., (2009), 92 pp. 4-14
[3]
J.B. Vermorken , R. Mesia, F. Rivera, E. Remenar, A. Kawecki, S. Rottey, et al.
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
N Engl J Med., (2008), 359 pp. 1116-1127
[4]
R. Hitt , J.J. Grau, A. López-Pousa, A. Berrocal, C. García-Girón, A. Irigoyen, et al.
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Ann Oncol., (2014), 25 pp. 216-225
[5]
M.G. Ghi , A. Paccagnella, D. Ferrari, P. Foa, D. Alterio, C. Codecá, et al.
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Ann Oncol., (2017), 28 pp. 2206-2212
[6]
R. Hitt , A. Irigoyen, H. Cortes-Funes, J.J. Grau, J.A. García-Sáenz, J.J. Cruz-Hernandez, Spanish Head and Neck Cancer Cooperative Group (TTCC).
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Ann Oncol., (2012), 23 pp. 1016-1022
[7]
R.L. Ferris , G. Blumenschein, J. Fayette, J. Guigay, D. Colevas, L. Licitra, et al.
Nivolumab for recurrent squamous-cell carcinoma of the head and neck.
N Engl J Med., (2016), 375 pp. 1856-1867
[8]
B. Burtness , K.J. Harrington, R. Greil, D. Souliéres, M. Tahara, G. de Castro, et al.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Lancet., (2019), 394 pp. 1915-1928
[9]
An imaging- based classification for the cervical nodes designed as an adjunct to recent clinically based nodal classifications.
Arch Otolaryngol Head Neck Surg., (1999), 125 pp. 388-396
[10]
Role of 18F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma.
World J Radiol., (2014), 6 pp. 177-191
